📧account manager: mark@advertrader.com
🔬Cutting edge biotechnology company with 💷£1.3m estimated marketing spend. B2B focus.
*High probability that the below brand is currently looking for advertising and marketing opportunities.
Brand / Company Name
Industry
Location
Growth Stage
Focus
Estimated Marketing Budget
Strategy (Previous)
ExpressionEdits’ marketing strategy includes establishing thought leadership through scientific publications, participating in industry conferences, and forming strategic partnerships. They focus on highlighting the unique advantages of their Genetic Syntax Engine and intronization technology. Their approach aims to educate the biotechnology community about their innovative solutions and attract potential collaborators and clients.
Agency
No agency attached.
Summary
ExpressionEdits is a cutting-edge biotechnology company dedicated to advancing protein expression through innovative AI-driven intronization technology. The company’s primary goal is to optimize genetic sequences to enhance the production of proteins that are typically difficult to express, significantly impacting therapeutic applications in both living organisms (in vivo) and laboratory settings (in vitro).
History
ExpressionEdits was founded in 2021 by Dr. Kärt Tomberg and Dr. Liliana Antunes. The idea for the company was sparked during the COVID-19 pandemic when the founders recognized the limitations of existing protein expression techniques. They developed a novel approach that involves integrating introns—previously considered non-essential DNA segments—into genetic constructs to improve the efficiency and yield of protein production. This breakthrough has allowed them to address a critical need in the biotechnology field.
Products / Services
Genetic Syntax Engine: An advanced AI platform designed to optimize genetic sequences by predicting their performance and integrating introns to enhance protein expression.
Intronization Technology: A proprietary method that involves inserting small, functional introns into genetic constructs to significantly improve gene expression.
Therapeutic Protein Production: Focused on developing high-value proteins for therapeutic use, overcoming previous challenges related to production scale and efficiency.
Financial Summary
ExpressionEdits successfully raised $13 million in seed funding. This capital infusion is intended to further develop their Genetic Syntax Engine, expand their pipeline of therapeutic proteins, and support their growth initiatives. The funding will also enable the company to explore new collaborations and enhance their gene therapy solutions.
Team
Dr. Kärt Tomberg: CEO and Co-founder, with a strong background in molecular biology and genetic engineering.
Dr. Rebecca Godfrey: COO, overseeing operations and strategic initiatives.
Dr. Leopold Parts: CTO, leading the technological advancements and development of the Genetic Syntax Engine.
Dr. Felicity Allen: Head of Data Analytics, specializing in data-driven insights to enhance genetic research.
Dr. Stijn van Dongen: Senior Data Operations Engineer, focusing on the integration and management of complex data systems.
Dr. Susanne Franssen: Senior Data Scientist, working on the computational aspects of genetic optimization.
Achievements
ExpressionEdits has achieved significant milestones in the biotechnology sector by improving protein expression techniques. Their innovative use of intronization has garnered attention and investment, positioning them as a leader in the field. The company’s work is paving the way for new therapeutic proteins that were previously difficult or impossible to produce at scale
Current / Previous Ad Campaign Messaging
𝙵𝚎𝚎𝚕𝚜 𝚕𝚒𝚔𝚎 𝚒𝚝’𝚜 𝚋𝚎𝚎𝚗 𝚊𝚐𝚎𝚜, 𝙻𝚘𝚗𝚍𝚘𝚗!
Excited to be back next Wednesday for the BIA TechBio UK conference.
Looking forward to catching up with everyone and making new connections in the biotech community.
If you’re attending, let’s make sure to meet – comment below or find me at the event.
hashtag#𝚃𝚎𝚌𝚑𝙱𝚒𝚘 hashtag#𝙽𝚎𝚝𝚠𝚘𝚛𝚔𝚒𝚗𝚐 hashtag#𝙻𝚘𝚗𝚍𝚘𝚗𝙴𝚟𝚎𝚗𝚝𝚜 hashtag#𝙱𝚒𝚘𝚝𝚎𝚌𝚑𝚗𝚘𝚕𝚘𝚐𝚢
We’re grateful to be part of the Cambridge biotech community and excited to see us being chosen for the 21toWatch longlist!
Interesting News
ExpressionEdits secures $13m to develop protein-based therapies
https://www.pharmaceutical-business-review.com/news/expressionedits-protein-based-therapies/
Estonian entrepreneur’s biotech startup bags $13 million seed to revolutionize protein production with AI-powered gene tech
https://arcticstartup.com/expressionedits-raises-13m-seed/
How To Pitch / Recommended Approach
Marketing Person
Marketing Person Details
Company
Account
Find Buyers
Contact
Copyright 2024 – Advertrader is a brand of Advertrader Ltd (Company No. 14934549) registered in England & Wales. Trademark #UK00003637221. Registered with the ICO (Ref: ZB632648).
